依库珠单抗治疗1例系统性红斑狼疮合并血栓性微血管病病例报道

刘恒, 廖盼丽, 王筱雯

中国当代儿科杂志 ›› 2025, Vol. 27 ›› Issue (9) : 1134-1139.

PDF(1052 KB)
HTML
PDF(1052 KB)
HTML
中国当代儿科杂志 ›› 2025, Vol. 27 ›› Issue (9) : 1134-1139. DOI: 10.7499/j.issn.1008-8830.2502059
病例报告

依库珠单抗治疗1例系统性红斑狼疮合并血栓性微血管病病例报道

作者信息 +

Eculizumab in the treatment of systemic lupus erythematosus complicated by thrombotic microangiopathy: a case report

Author information +
文章历史 +

摘要

患儿,女,10岁10个月,因乏力、面色苍白3个月,皮疹2周就诊。完善检查发现患儿贫血、血小板减少、血尿蛋白尿合并肾功能不全、低补体血症、多浆膜腔积液、抗核抗体及抗双链DNA抗体阳性,初步诊断为系统性红斑狼疮、狼疮性肾炎。给予糖皮质激素冲击、静脉注射免疫球蛋白冲击及血浆置换治疗,效果欠佳。住院过程中患儿持续贫血、血小板减少、肾功能异常及乳酸脱氢酶升高,补体因子H、I均下降,C3转化酶抗体升高,ADAMTS13活性正常,考虑诊断为系统性红斑狼疮继发补体介导的血栓性微血管病,给予依库珠单抗2次(600 mg/次)治疗后病情缓解。系统性红斑狼疮合并血栓性微血管病患者病情重,预后差,早期识别、积极干预可改善预后。

Abstract

The patient was a girl aged 10 years and 10 months, with weakness, pale complexion, and rash as the initial presentation. She had the manifestations of anemia, thrombocytopenia, hematuria-proteinuria with renal insufficiency, hypocomplementemia, polyserositis, and positive anti-nuclear antibody and anti-dsDNA antibody. The girl was initially diagnosed with systemic lupus erythematosus and lupus nephritis. She demonstrated a suboptimal response to methylprednisolone pulse therapy, intravenous immunoglobulin administration, and therapeutic plasma exchange. She had persistent anemia, thrombocytopenia, abnormal renal function, elevated lactate dehydrogenase, decreased complement factors H and I, increased antibodies to C3 converting enzyme, and normal ADAMTS13 activity. She was diagnosed with complement-mediated hemolytic thrombotic microangiopathy secondary to systemic lupus erythematosus. The patient's condition improved after treatment with two doses of eculizumab (600 mg per dose). Patients with systemic lupus erythematosus complicated by thrombotic microangiopathy often have a severe disease course and poor prognosis; therefore, early recognition and aggressive intervention are crucial for improving outcomes.

关键词

系统性红斑狼疮 / 血栓性微血管病 / 依库珠单抗 / 儿童

Key words

Systemic lupus erythematosus / Thrombotic microangiopathy / Eculizumab / Child

引用本文

导出引用
刘恒, 廖盼丽, 王筱雯. 依库珠单抗治疗1例系统性红斑狼疮合并血栓性微血管病病例报道[J]. 中国当代儿科杂志. 2025, 27(9): 1134-1139 https://doi.org/10.7499/j.issn.1008-8830.2502059
Heng LIU, Pan-Li LIAO, Xiao-Wen WANG. Eculizumab in the treatment of systemic lupus erythematosus complicated by thrombotic microangiopathy: a case report[J]. Chinese Journal of Contemporary Pediatrics. 2025, 27(9): 1134-1139 https://doi.org/10.7499/j.issn.1008-8830.2502059

参考文献

[1]
沈南, 赵毅, 段利华, 等. 系统性红斑狼疮诊疗规范[J]. 中华内科杂志, 2023, 62(7): 775-784. DOI: 10.3760/cma.j.cn112138-20221027-00793 .
[2]
George JN, Nester CM. Syndromes of thrombotic microangiopathy[J]. N Engl J Med, 2014, 371(7): 654-666. DOI: 10.1056/NEJMra1312353 .
[3]
李晓洁, 魏雅琴, 高春林, 等. 系统性红斑狼疮合并血栓性微血管病的病因及治疗[J]. 中华儿科杂志, 2023, 61(8): 753-756. DOI: 10.3760/cma.j.cn112140-20221231-01078 .
[4]
Sun F, Wang X, Wu W, et al. TMA secondary to SLE: rituximab improves overall but not renal survival[J]. Clin Rheumatol, 2018, 37(1): 213-218. DOI: 10.1007/s10067-017-3793-4 .
[5]
Kwok SK, Ju JH, Cho CS, et al. Thrombotic thrombocytopenic purpura in systemic lupus erythematosus: risk factors and clinical outcome: a single centre study[J]. Lupus, 2009, 18(1): 16-21. DOI: 10.1177/0961203308094360 .
[6]
张丹, 赖建铭, 李明, 等. 儿童系统性红斑狼疮合并血栓性微血管病临床特点及诱导缓解治疗疗效[J]. 中国新药与临床杂志, 2024, 43(2): 103-106. DOI: 10.14109/j.cnki.xyylc.2024.02.04 .
[7]
Hamasaki K, Mimura T, Kanda H, et al. Systemic lupus erythematosus and thrombotic thrombocytopenic purpura: a case report and literature review[J]. Clin Rheumatol, 2003, 22(4/5): 355-358. DOI: 10.1007/s10067-003-0742-1 .
[8]
中国罕见病联盟儿童非典型溶血尿毒综合征专业委员会, 国家儿童医学中心(首都医科大学附属北京儿童医院), 《中华实用儿科临床杂志》编辑委员会. 中国儿童非典型溶血尿毒综合征诊治专家共识(2023版)[J]. 中华实用儿科临床杂志, 2023, 38(6): 401-412. DOI: 10.3760/cma.j.cn101070-20230328-00257 .
[9]
Scully M, Cataland S, Coppo P, et al. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies[J]. J Thromb Haemost, 2017, 15(2): 312-322. DOI: 10.1111/jth.13571 .
[10]
Loirat C, Fakhouri F, Ariceta G, et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children[J]. Pediatr Nephrol, 2016, 31(1): 15-39. DOI: 10.1007/s00467-015-3076-8 .
[11]
陈志威, 叶霜. 系统性红斑狼疮合并血栓性微血管病[J]. 中国实用内科杂志, 2015, 35(10): 825-827. DOI: 10.7504/nk2015090106 .
[12]
Scully M, Hunt BJ, Benjamin S, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies[J]. Br J Haematol, 2012, 158(3): 323-335. DOI: 10.1111/j.1365-2141.2012.09167.x .
[13]
李嘉欣, 张卓莉. 系统性红斑狼疮合并血栓性微血管病的诊治及预后[J]. 中华风湿病学杂志, 2018, 22(9): 642-645. DOI: 10.3760/cma.j.issn.1007-7480.2018.09.015 .
[14]
殷蕾, 茅幼英, 周征宇, 等. 儿童系统性红斑狼疮并发血栓性微血管病的临床特点和早期识别[J]. 中国小儿急救医学, 2021, 28(10): 868-873. DOI: 10.3760/cma.j.issn.1673-4912.2021.10.006 .
[15]
Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype[J]. Clin J Am Soc Nephrol, 2010, 5(10): 1844-1859. PMCID: PMC2974386. DOI: 10.2215/CJN.02210310 .
[16]
Zuber J, Fakhouri F, Roumenina LT, et al. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies[J]. Nat Rev Nephrol, 2012, 8(11): 643-657. DOI: 10.1038/nrneph.2012.214 .
[17]
章玲霞, 王晶晶, 金艳艳, 等. 伊库珠单抗治疗儿童系统性红斑狼疮合并血栓性微血管病的2例经验分享及文献复习[J]. 中华肾脏病杂志, 2023, 39(12): 942-946. DOI: 10.3760/cma.j.cn441217-20230504-00502 .
[18]
Aigner C, Gaggl M, Stemer G, et al. Eculizumab use in a tertiary care nephrology center: data from the Vienna TMA cohort[J]. J Nephrol, 2022, 35(2): 451-461. PMCID: PMC8927043. DOI: 10.1007/s40620-021-00981-8 .
[19]
Wright RD, Bannerman F, Beresford MW, et al. A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy[J]. BMC Nephrol, 2020, 21(1): 245. PMCID: PMC7329551. DOI: 10.1186/s12882-020-01888-5 .
[20]
Bermea RS, Sharma N, Cohen K, et al. Use of eculizumab in atypical hemolytic uremic syndrome, complicating systemic lupus erythematosus[J]. J Clin Rheumatol, 2016, 22(6): 320-323. DOI: 10.1097/RHU.0000000000000423 .
[21]
El-Husseini A, Hannan S, Awad A, et al. Thrombotic microangiopathy in systemic lupus erythematosus: efficacy of eculizumab[J]. Am J Kidney Dis, 2015, 65(1): 127-130. DOI: 10.1053/j.ajkd.2014.07.031 .
[22]
Stiles KP, Yuan CM, Chung EM, et al. Renal biopsy in high-risk patients with medical diseases of the kidney[J]. Am J Kidney Dis, 2000, 36(2): 419-433. DOI: 10.1053/ajkd.2000.8998 .
[23]
Mustafa KN, Aladily TN, Shomaf MS, et al. Renal biopsy findings in lupus nephritis[J]. Saudi J Kidney Dis Transpl, 2011, 22(4): 815-817.
[24]
Macedo AC, Isaac L. Systemic lupus erythematosus and deficiencies of early components of the complement classical pathway[J]. Front Immunol, 2016, 7: 55. PMCID: PMC4764694. DOI: 10.3389/fimmu.2016.00055 .
[25]
Belot A, Cimaz R. Monogenic forms of systemic lupus erythematosus: new insights into SLE pathogenesis[J]. Pediatr Rheumatol Online J, 2012, 10(1): 21. PMCID: PMC3489560. DOI: 10.1186/1546-0096-10-21 .

脚注

所有作者声明无利益冲突。

基金

武汉市科技局知识创新项目(2023020201010197)
武汉儿童医院儿童肾病研究室建设项目(2022FEYJS003)
武汉市出生缺陷防治临床医学研究中心建设项目(武科[2023]123号)

编委: 张辉

版权

版权所有 © 2023中国当代儿科杂志
PDF(1052 KB)
HTML

Accesses

Citation

Detail

段落导航
相关文章

/